WO2005037280A1 - Muscarinic acetycholine receptor antagonists - Google Patents

Muscarinic acetycholine receptor antagonists Download PDF

Info

Publication number
WO2005037280A1
WO2005037280A1 PCT/US2004/033638 US2004033638W WO2005037280A1 WO 2005037280 A1 WO2005037280 A1 WO 2005037280A1 US 2004033638 W US2004033638 W US 2004033638W WO 2005037280 A1 WO2005037280 A1 WO 2005037280A1
Authority
WO
WIPO (PCT)
Prior art keywords
endo
bicyclo
diphenyl
alkyl
methyl
Prior art date
Application number
PCT/US2004/033638
Other languages
French (fr)
Inventor
Jakob Busch-Petersen
Michael R. Palovich
Zehong Wan
Hongxing Yan
Chongjie Zhu
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2004281724A priority Critical patent/AU2004281724B2/en
Priority to AP2006003566A priority patent/AP1828A/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to CA2542657A priority patent/CA2542657C/en
Priority to DK04794886.4T priority patent/DK1677795T3/en
Priority to US10/575,839 priority patent/US7276521B2/en
Priority to DE602004030930T priority patent/DE602004030930D1/en
Priority to EP04794886A priority patent/EP1677795B1/en
Priority to JP2006535591A priority patent/JP2007508390A/en
Priority to PL04794886T priority patent/PL1677795T3/en
Priority to AP2007004238A priority patent/AP2007004238A0/en
Priority to SI200431631T priority patent/SI1677795T1/en
Priority to AP2007004239A priority patent/AP2007004239A0/en
Priority to EA200600773A priority patent/EA009899B1/en
Priority to MXPA06004244A priority patent/MXPA06004244A/en
Priority to NZ546312A priority patent/NZ546312A/en
Priority to AT04794886T priority patent/ATE494285T1/en
Priority to BRPI0415361-8A priority patent/BRPI0415361A/en
Publication of WO2005037280A1 publication Critical patent/WO2005037280A1/en
Priority to EC2006006468A priority patent/ECSP066468A/en
Priority to IL174843A priority patent/IL174843A0/en
Priority to IS8441A priority patent/IS2918B/en
Priority to NO20062042A priority patent/NO20062042L/en
Priority to US11/766,318 priority patent/US7579361B2/en
Priority to US11/766,371 priority patent/US7576096B2/en
Priority to IL188112A priority patent/IL188112A/en
Priority to HR20110232T priority patent/HRP20110232T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Definitions

  • This invention relates to novel derivatives of 8-azoniabicyclo[3,2,l]octanes, pharmaceutical compositions, processes for their preparation, and use thereof in treating M3 muscarinic acetylcholine receptor mediated diseases.
  • BACKGROUND OF THE INVENTION Acetylcholine released from cholinergic neurons in the peripheral and central nervous systems affects many different biological processes through interaction with two major classes of acetylcholine receptors - the nicotinic and the muscarinic acetylcholine receptors.
  • Muscarinic acetylcholine receptors belong to the superfamily of G-protein coupled receptors that have seven transmembrane domains. There are five subtypes of mAChRs, termed M1-M5, and each is the product of a distinct gene. Each of these five subtypes displays unique pharmacological properties. Muscarinic acetylcholine receptors are widely distributed in vertebrate organs, and these receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, bladder and gastrointestinal tract, M3 mAChRs mediate contractile responses. For review, please see ⁇ Brown 1989 247 /id ⁇ .
  • Muscarinic acetylcholine receptor dysfunction has been noted in a variety of different pathophysiological states. For instance, in asthma and chronic obstructive pulmonary disease (COPD), inflammatory conditions lead to loss of inhibitory M2 muscarinic acetylcholine autoreceptor function on parasympathetic nerves supplying the pulmonary smooth muscle, causing increased acetylcholine release following vagal nerve stimulation.
  • This mAChR dysfunction results in airway hyperreactivity mediated by increased stimulation of M3 mAChRs ⁇ Costello, Evans, et al. 1999 72 /id ⁇ ⁇ Minette, Lammers, et al. 1989 248 /id ⁇ .
  • IBD inflammatory bowel disease
  • This invention provides for a method of treating a muscarinic acetylcholine receptor (mAChR) mediated disease, wherein acetylcholine binds to an M3 mAChR and which method comprises administering an effective amount of a compound of
  • This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I) or Formula (II) [except the compound of Formula (II) with R2 and R3 as 2- thiophene and R4 as -OC(O)CH 3 ] or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I) or Formula
  • Formula (II), and pharmaceutical compositions comprising a compound of Formula (I) or Formula (II), and a pharmaceutical carrier or diluent.
  • Compounds of Formula (I) or Formula (II) useful in the present invention are represented by the structure:
  • RI " represents an anion associated with the positive charge of the N atom.
  • RI " may be but is not limited to chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate;
  • R2 and R3 are independently selected from the group consisting of straight or branched chain lower alkyl groups (having preferably from 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms), heterocycloalkyl (having 5 to 6 carbon atoms) and N or O as the heteroatom, heterocycloalkyl-alkyl (having 6 to 10 carbon atoms) and N or O as the heteroatom, aryl, optionally substituted aryl, heteroaryl, and optionally substituted heteroaryl;
  • R4 is sleeted from the group consisting of (C ⁇ -C 6 )alkyl, (C 3 -C ⁇ 2 )cycloalkyl, (C 3 - C 7 )heterocycloalkyl, (d-C 6 )alkyl(C 3 - C 7 )heterocycloalkyl, aryl, heteroaryl, (C 1 -C 6 )alkyl-aryl, (C 1 -C 6 )alkyl-heteroaryl, -OR5, -CH 2 OR5, -CH 2 OH, -CN, -CF 3 , -CH 2 O(CO)R6, -CO 2 R7, -CH 2 NH 2 , - CH 2 N(R7)SO 2 R5, -SO 2 N(R7)(R8), -CON(R7)(R8), -CH 2 N(R8)CO(R6), - CH 2 N(R8)SO 2 (R6), -CH 2 N(R8)CO
  • R5 is selected from the group consisting of (d-C 6 )alkyl, (C ⁇ -C 6 )alkyl(C 3 - C 12 )cycloalkyl, (C 1 -C 6 )alkyl(C 3 -C 7 )heterocycloalkyl, (C 1 -C 6 )alkyl-aryl, (d-C 6 )alkyl- heteroaryl;
  • R6 is selected from the group consisting of (C]-C 6 )alkyl, (C 3 -C] 2 )cycloalkyl, (C 3 - C 7 )heterocycloalkyl, (C 1 -C 6 )alkyl(C 3 -C 12 )cycloalkyl, (C 1 -C 6 )alkyl(C 3 - C 7 )heterocycloalkyl, aryl, heteroaryl, (d-C 6 )alkyl-aryl, (C ⁇ -C 6 )alkyl-heteroaryl;
  • R7 and R8 are, independently, selected from the group consisting of H, (d-C 6 )alkyl, (C 3 -C !2 )cycloalkyl, (C 3 -C 7 )heterocycloalkyl, (C ⁇ -C 6 )alkyl(C 3 -C 12 )cycloalkyl, (C r C 6 )alkyl(C 3 -C )heterocycloalkyl, (C ⁇ -C 6 )alkyl-aryl, and (C ⁇ -C 6 )alkyl-heteroaryl.
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
  • pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II) may also be formed with a pharmaceutically acceptable cation.
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.
  • C ⁇ _ ⁇ oalkyl or “alkyl” - both straight and branched chain moieties of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, n-propyl, wo-propyl, n-butyl, sec-butyl, w ⁇ -butyl, tert-butyl, n-pentyl and the like.
  • cycloalkyl is used herein to mean cyclic moiety, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • alkenyl is used herein at all occurrences to mean straight or branched chain moiety of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl and the like.
  • heteroaryl - phenyl and naphthyl; • “heteroaryl” (on its own or in any combination, such as “heteroaryloxy", or “heteroaryl alkyl”) - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, tetrazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.
  • heterocyclic on its own or in any combination, such as “heterocyclicalkyl)
  • a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, thiomorpholine, or imidazolidine.
  • sulfur may be optionally oxidized to the sulfone or the sulfoxide.
  • arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean Ci-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.
  • sulfinyl - the oxide S (O) of the corresponding sulfide
  • thio refers to the sulfide
  • sulfonyl refers to the fully oxidized S(O)2 moiety.
  • Ri moieties may together form a 5 or 6 membered saturated or unsaturated ring
  • an aromatic ring system such as naphthalene, or is a phenyl moiety having attached a 6 membered partially saturated or unsaturated ring such as a C cycloalkenyl, i.e. hexene, or a C5 cycloalkenyl moiety, such as cyclopentene.
  • Preferred compounds useful in the present invention include:
  • More preferred compounds useful in the present invention include:
  • NaBH(OAc) 3 furnished amine 20 that was easily converted to amide 21, carbamide 22, urea 23 and sulfonamide 24.
  • Compounds with structures similar to 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 were converted to corresponding ammonium salts by reacting with appropriate reaction reagents such as MeBr and Mel (not shown in the scheme). Appropriate protection and deprotection methods were utilized in some preparation procedures.
  • Scheme III See Section III.
  • reaction mixture was heated to reflux for 5 d. Each day, an additional 0.2mL iodomethane and O.lmL potassium hydroxide was added. Upon completion, the reaction mixture was cooled to room temperature, diluted with methylenechloride and washed with water. The aqueous layer was extracted with methylenechloride and the combined organic layers were washed with brine, dried over MgSO 4 and concentrated in vacuo. The crude product was recrystallized from methylenechloride/ethyl acetate to give 109mg of the title compound: LCMS (ES) m z 362 (M) + .
  • inhibitory effects of compounds at the M3 mAChR of the present invention are determined by the following in vitro and in vivo assay:
  • the dye-containing media was then aspirated, replaced with fresh media (without Fluo-3 AM), and cells were incubated for 10 minutes at 37° C. Cells were then washed 3 times and incubated for 10 minutes at 37° C in 100 ⁇ l of assay buffer (0.1% gelatin (Sigma), 120 mM NaCl, 4.6 mM KC1, 1 mM KH 2 PO4, 25 mM NaH CO3, 1.0 mM CaCl , 1.1 mM MgCi2, 11 mM glucose, 20mM
  • assay buffer (0.1% gelatin (Sigma), 120 mM NaCl, 4.6 mM KC1, 1 mM KH 2 PO4, 25 mM NaH CO3, 1.0 mM CaCl , 1.1 mM MgCi2, 11 mM glucose, 20mM
  • HEPES HEPES (pH 7.4)). 50 ⁇ l of compound (lxlO" 1 1 - lxlO" 5 M final in the assay) was added and the plates were incubated for 10 min. at 37° C. Plates were then placed into a fluorescent light intensity plate reader (FLIPR, Molecular Probes) where the dye loaded cells were exposed to excitation light (488 nm) from a 6 watt argon laser. Cells were activated by adding 50 ⁇ l of acetylcholine (0.1-10 nM final), prepared in buffer containing 0.1 % BSA, at a rate of 50 ⁇ l/sec. Calcium mobilization, monitored as change in cytosolic calcium concentration, was measured as change in 566 nm emission intensity.
  • FLIPR fluorescent light intensity plate reader
  • the change in emission intensity is directly related to cytosolic calcium levels ' '.
  • the emitted fluorescence from all 96 wells is measured simultaneously using a cooled CCD camera. Data points are collected every second. This data was then plotting and analyzed using GraphPad PRISM software.
  • Mice were pretreated with 50 ⁇ l of compound (0.003-10 ⁇ g/mouse) in 50 ⁇ l of vehicle (10% DMSO) intranasally, and were then placed in the plethysmography chamber. Once in the chamber, the mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes.
  • mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Description

MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS FIELD OF THE INVENTION This invention relates to novel derivatives of 8-azoniabicyclo[3,2,l]octanes, pharmaceutical compositions, processes for their preparation, and use thereof in treating M3 muscarinic acetylcholine receptor mediated diseases. BACKGROUND OF THE INVENTION Acetylcholine released from cholinergic neurons in the peripheral and central nervous systems affects many different biological processes through interaction with two major classes of acetylcholine receptors - the nicotinic and the muscarinic acetylcholine receptors. Muscarinic acetylcholine receptors (mAChRs) belong to the superfamily of G-protein coupled receptors that have seven transmembrane domains. There are five subtypes of mAChRs, termed M1-M5, and each is the product of a distinct gene. Each of these five subtypes displays unique pharmacological properties. Muscarinic acetylcholine receptors are widely distributed in vertebrate organs, and these receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, bladder and gastrointestinal tract, M3 mAChRs mediate contractile responses. For review, please see {Brown 1989 247 /id}. Muscarinic acetylcholine receptor dysfunction has been noted in a variety of different pathophysiological states. For instance, in asthma and chronic obstructive pulmonary disease (COPD), inflammatory conditions lead to loss of inhibitory M2 muscarinic acetylcholine autoreceptor function on parasympathetic nerves supplying the pulmonary smooth muscle, causing increased acetylcholine release following vagal nerve stimulation. This mAChR dysfunction results in airway hyperreactivity mediated by increased stimulation of M3 mAChRs {Costello, Evans, et al. 1999 72 /id} {Minette, Lammers, et al. 1989 248 /id}. Similarly, inflammation of the gastrointestinal tract in inflammatory bowel disease (IBD) results in M3 mAChR-mediated hypermotility
{Oprins, Meijer, et al. 2000 245 /id}. Incontinence due to bladder hypercontractility has also been demonstrated to be mediated through increased stimulation of M3 mAChRs {Hegde & Eglen 1999 251 /id}. Thus the identification of subtytpe-selective mAChR antagonists may be useful as therapeutics in these mAChR-mediated diseases. Despite the large body of evidence supporting the use of anti-muscarinic receptor therapy for treatment of a variety of disease states, relatively few anti- muscarinic compounds are in use in the clinic. Thus, there remains a need for novel compounds that are capable of causing blockade at M3 mAChRs. Conditions associated with an increase in stimulation of M3 mAChRs, such as asthma, COPD, IBD and urinary incontinence would benefit by compounds that are inhibitors of mAChR binding.
SUMMARY OF THE INVENTION This invention provides for a method of treating a muscarinic acetylcholine receptor (mAChR) mediated disease, wherein acetylcholine binds to an M3 mAChR and which method comprises administering an effective amount of a compound of
Formula (I) or Formula (II) [except the compound of Formula (II) with R2 and R3 as 2- thiophene and R4 as -OC(O)CH3] or a pharmaceutically acceptable salt thereof. This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I) or Formula
(II). The present invention also provides for the novel compounds of Formula (I) or
Formula (II), and pharmaceutical compositions comprising a compound of Formula (I) or Formula (II), and a pharmaceutical carrier or diluent. Compounds of Formula (I) or Formula (II) useful in the present invention are represented by the structure:
Figure imgf000003_0001
wherein: the H atom indicated is in the exo position; RI" represents an anion associated with the positive charge of the N atom. RI" may be but is not limited to chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate;
R2 and R3 are independently selected from the group consisting of straight or branched chain lower alkyl groups (having preferably from 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms), heterocycloalkyl (having 5 to 6 carbon atoms) and N or O as the heteroatom, heterocycloalkyl-alkyl (having 6 to 10 carbon atoms) and N or O as the heteroatom, aryl, optionally substituted aryl, heteroaryl, and optionally substituted heteroaryl;
R4 is sleeted from the group consisting of (Cι-C6)alkyl, (C3-Cι2)cycloalkyl, (C3- C7)heterocycloalkyl,
Figure imgf000004_0001
(d-C6)alkyl(C3- C7)heterocycloalkyl, aryl, heteroaryl, (C1-C6)alkyl-aryl, (C1-C6)alkyl-heteroaryl, -OR5, -CH2OR5, -CH2OH, -CN, -CF3, -CH2O(CO)R6, -CO2R7, -CH2NH2, - CH2N(R7)SO2R5, -SO2N(R7)(R8), -CON(R7)(R8), -CH2N(R8)CO(R6), - CH2N(R8)SO2(R6), -CH2N(R8)CO2(R5), -CH2N(R8)CONH(R7);
R5 is selected from the group consisting of (d-C6)alkyl, (Cι-C6)alkyl(C3- C12)cycloalkyl, (C1-C6)alkyl(C3-C7)heterocycloalkyl, (C1-C6)alkyl-aryl, (d-C6)alkyl- heteroaryl;
R6 is selected from the group consisting of (C]-C6)alkyl, (C3-C]2)cycloalkyl, (C3- C7)heterocycloalkyl, (C1-C6)alkyl(C3-C12)cycloalkyl, (C1-C6)alkyl(C3- C7)heterocycloalkyl, aryl, heteroaryl, (d-C6)alkyl-aryl, (Cι-C6)alkyl-heteroaryl;
R7 and R8 are, independently, selected from the group consisting of H, (d-C6)alkyl, (C3-C!2)cycloalkyl, (C3-C7)heterocycloalkyl, (Cι-C6)alkyl(C3-C12)cycloalkyl, (Cr C6)alkyl(C3-C )heterocycloalkyl, (Cι-C6)alkyl-aryl, and (Cι-C6)alkyl-heteroaryl. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of Formula (I) or Formula (II) may also be formed with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. The following terms, as used herein, refer to: • "halo" - all halogens, that is chloro, fluoro, bromo and iodo. • "Cι_ιoalkyl" or "alkyl" - both straight and branched chain moieties of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, n-propyl, wo-propyl, n-butyl, sec-butyl, wσ-butyl, tert-butyl, n-pentyl and the like. • "cycloalkyl" is used herein to mean cyclic moiety, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like. • "alkenyl" is used herein at all occurrences to mean straight or branched chain moiety of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl and the like. • "aryl" - phenyl and naphthyl; • "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, tetrazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole. • "heterocyclic" (on its own or in any combination, such as "heterocyclicalkyl")
- a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, thiomorpholine, or imidazolidine. Furthermore, sulfur may be optionally oxidized to the sulfone or the sulfoxide. • "arylalkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean Ci-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated. • "sulfinyl" - the oxide S (O) of the corresponding sulfide, the term "thio" refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S(O)2 moiety. • "wherein two Ri moieties (or two Y moieties) may together form a 5 or 6 membered saturated or unsaturated ring" is used herein to mean the formation of an aromatic ring system, such as naphthalene, or is a phenyl moiety having attached a 6 membered partially saturated or unsaturated ring such as a C cycloalkenyl, i.e. hexene, or a C5 cycloalkenyl moiety, such as cyclopentene.
Preferred compounds useful in the present invention include:
(Endo)-3-(2-methoxy-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1]octane iodide;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl-propionitrile;
(Endo)-8-methyl-3-(2,2,2-triphenyl-ethyl)-8-aza-bicyclo[3.2.1 Joctane;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionamide;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionic acid; (Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 Joctane iodide;
(Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 ]octane bromide;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propan-l-ol; N-Benzyl-3-((endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl- propionamide;
(Endo)-3-(2-carbamoyl-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 ]octane iodide;
1 -Benzyl-3 -[3 -((endo)-8-methyl-8-aza-bicyclo [3.2.1] oct-3 -yl)-2,2-diphenyl-propyl] - urea; l-Ethyl-3-[3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea;
N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-acetamide; N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-benzamide;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-di-thiophen-2-yl-propionitrile;
(Endo)-3-(2-cyano-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1]octane iodide; N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]- benzenesulfonamide ;
[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea;
N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]- methanesulfonamide; and (Endo)-3-{2,2-diphenyl-3-[(l-phenyl-methanoyl)-amino]-propyl}-8,8-dimethyl-8- azonia-bicyclo[3.2.1 ]octane bromide.
More preferred compounds useful in the present invention include:
(Endo)-3-(2-methoxy-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1]octane iodide; (Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane iodide;
(Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide;
(Endo)-3-(2-carbamoyl-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 joctane iodide;
(Endo)-3-(2-cyano-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1]octane iodide; and
(Endo)-3-{2,2-diphenyl-3-[(l-phenyl-methanoyl)-amino]-propyl}-8,8-dimethyl-8- azonia-bicyclo[3.2.1 Joctane bromide.
Methods of Preparation.
Preparation The compounds of Formula (I) and Formula (II) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below. The synthesis provided for these Schemes is applicable for producing compounds of
Formula (I) and Formula (II) having a variety of different RI, R2, R3 and R4 which are reacted, employing substituents which are suitable protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. While some schemes are shown with compounds only of Formula (II), this is merely for illustration purpose only. The general preparation method is shown in Scheme I. The synthesis started with compound 1. Reduction with lithium aluminium hydride (LAH) afforded alcohol 2. Displacement with iodine provided 3. Coupling reaction with the anion derived from HCR2(R3)(R4) then furnished compound 4, which was easily converted to ammonium salt 5. Scheme I.
Figure imgf000008_0001
A more specific preparation method leading to compounds with Formula (II) is outlined in Scheme II. Alkylation of ester HC(Ph)2CO CH3 with 3 afforded compound 6. Hydrolysis of 6 generated acid 7. 1,3 -Dicyclohexylcarbodumide (DCC) mediated condensation of the acid with alcohol (R7)OH then furnished ester 8. Condensation of acid 7 with amine (R7)(R8)NH under suitable amide coupling conditions well known to those skilled in the art such as l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HC1) and 1-hydroxybenzotriazole hydrate (HOBt) provided amide 9. Reduction of 6 generated alcohol 10. Reaction of 10 with acid chloride (R6)COCl or acid (R6)CO2H afforded ester 11. Alkylation of 10 with appropriate reagents such as (R5)Br then furnished 12. Compounds with structures similar to 6, 7, 8, 9, 10, 11 and 12 were converted to corresponding ammonium salts by reacting with appropriate reaction reagents such as MeBr and Mel (not shown in the scheme). Appropriate protection and deprotection methods were utilized in some preparation procedures. Scheme II.
Figure imgf000009_0001
A more specific preparation method leading to compounds with Formula (II) is outlined in Scheme III. Alkylation of HC(Ph)2CN with 3 provided nitrile 13. Hydrolysis of 13 under either basic conditions (e.g., NaOH and H O2) or acidic conditions (e.g., H2SO4) afforded amide 14. Reduction of 13 led to amine 15 that was conviently transfromed to amide 16, carbamide 17, sulfonamide 18 and urea 19. Condensation of 15 with aldehyde (R8)CH(O) followed by reduction with
NaBH(OAc)3 furnished amine 20 that was easily converted to amide 21, carbamide 22, urea 23 and sulfonamide 24. Compounds with structures similar to 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 were converted to corresponding ammonium salts by reacting with appropriate reaction reagents such as MeBr and Mel (not shown in the scheme). Appropriate protection and deprotection methods were utilized in some preparation procedures. Scheme III.
Figure imgf000010_0001
A more specific preparation method leading to compounds with Formula (II) is outlined in Scheme IV. Alkylation of 25 with (R5)Br provided 26. Reaction of 25 with Lawesson's reagent afforded 27. Oxidation of 27 with SO2Cl2 and KNO3 furnished 28 that was converted to either 29 or sulfonamide 30. Compounds with structures similar to 26, 27, 29 and 30 were easily converted to the corresponding ammonium salts by reacting with appropriate reaction reagents such as MeBr and Mel (not shown in the scheme). Appropriate protection and deprotection methods were utilized in some preparation procedures. Scheme IV
Figure imgf000011_0001
SYNTHETIC EXAMPLES The following examples are provided as illustrative of the present invention but not limiting in any way: Example 1
Figure imgf000011_0002
(Endo)-3-(2-methoxy-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclor3.2.11octane iodide To a solution of 2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-l,l-dithiophen-2-yl- ethanol (prepared according to US2800482) (212mg, 0.64mmol) in 5 mL methylenechloride and iodomethane (0.40mL, 6.4 mmol), 50% aqueous potassium hydroxide (0.25mL, 3.2 mmol) and tetrabutylammonium chloride (5mg, 3 mol%) was added. The reaction mixture was heated to reflux for 5 d. Each day, an additional 0.2mL iodomethane and O.lmL potassium hydroxide was added. Upon completion, the reaction mixture was cooled to room temperature, diluted with methylenechloride and washed with water. The aqueous layer was extracted with methylenechloride and the combined organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo. The crude product was recrystallized from methylenechloride/ethyl acetate to give 109mg of the title compound: LCMS (ES) m z 362 (M)+.
Example 2
Figure imgf000012_0001
3-((Endo)-8-methyl-8-aza-bicvclo[3.2.11oct-3-yl)-2,2-diphenyl-propionitrile 2a) Preparation of ((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-methanol A mixture of 1,1-dimethylethyl (endo)-3-(hydroxymethyl)-8-azabicyclo[3.2.1J octane-8-carboxylate (0.50 g, 2.05 mmol) and LiAlH4 (6.16 mL, 1.0 M in THF, 6.16 mmol) was heated at 80°C with a microwave reactor for 60 min. The solution was then mixed with saturated Na2SO4 solution, filtered through celite and concentrated to afford the title compound (0.31 g, 97 %): LCMS (ES) m/z 156 (M+H)+; 1H- NMR(CDC13) 5 1.28 (s, 1H), 1.59 (m, 4H), 1.90 (m, 1H), 2.13 (m, 4H), 2.32 (s, 3H), 3.17 (s, 2H), 3.59 (d, 2H).
2b) Preparation of (endo)-3-iodomethyl-8-methyl-8-aza-bicyclo[3.2.1 Joctane A solution of iodine (6.67 g, 25.8 mmol) and ((endo)-8-methyl-8-aza- bicyclo[3.2.1]oct-3-yl)-methanol (2.0 g, 12.9 mmol) in CH,C12 (120 mL) was mixed with PPh3 (on resin, 8.6 g, 3 mmol/g, 25.8 mmol). The resultant mixture was stirred for 17 hours, filtered and concentrated to afford the title compound (2.63 g, 77 %): LCMS (ES) m/z 266 (M+H)+; Η-NMR(CDC13) δ 2.05 (m, 4H), 2.39 (m, 3H), 2.79 (d, 3H), 2.98 (m, 2H), 3.45 (d, 2H), 3.81 (s, 2H).
2c) Preparation of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propionitrile A solution of (endo)-3-iodomethyl-8-methyl-8-aza-bicyclo[3.2.1]octane(1.06 g, 4.0 mmol) and Ph2CHCN (2.32 g, 12.0 mmol) in DMF (20 mL) was mixed with NaH (0.288 g, 12.0 mmol). The resultant mixture was stirred at room temperature for 60 minutes. Filtration and purification via a reverse phase HPLC (Gilson) then afforded the title compound (1.16 g, 93 %): LCMS (ES) m/z 331 (M+H)+; Η-NMR(CDC13) δ 1.64 (m, 2H), 2.14 (m, 1H), 2.26 (m, 2H), 2.34 (m, 2H), 2.52 (m, 2H), 2.75 (m, 5H), 3.83 (s, 2H), 7.39 (d, 10H). Example 3
Figure imgf000013_0001
(Endo)-8-methyl-3-('2,2,2-triphenyl-ethyl)-8-aza-bicvclo[3.2.1 Joctane A solution of triphenylmethane (0.276 g, 1.13 mmol) in THF (0.5 mL) was mixed with n-BuLi (0.706 mL, 1.6 M in Hexane, 1.13 mmol). The solution was stirred for 10 minutes and added by a solution of (endo)-3-iodomethyl-8-methyl-8-aza- bicyclo[3.2.1 Joctane (100 mg, 0.377 mmol) in DMF (1.0 mL). The mixture was stirred at room temperature for 60 minutes, mixed with H2O (0.1 mL), concentrated and filtered. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (23.8 mg, 17 %): LCMS (ES) m/z 382 (M+H)+; 1H-NMR(CDC13) δ 1.07 (d, 2H), 2.12 (m, 1H), 2.22 (m, 4H), 2.31 (m, 2H), 2.65 (d, 3H), 2.97 (d, 2H), 3.63 (s, 2H), 7.21 (m, 3H), 7.30 (d, 12H).
Figure imgf000014_0001
3-((Endo)-8-methyl-8-aza-bicvclor3.2.1Joct-3-yl)-2,2-diphenyl-propionamide A solution of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propionitrile (53 mg, 0.16 mmol) in CH2C12 (0. 25 mL) was mixed with H SO4 (0.28 mL, 96 %) and stirred at 40°C for 30 hours. The mixture was then poured into ice, neutralized with NH3.H2O, extracted with EtOAc and concentrated. The resultant residue was dissolved in DMSO and filtered. Purification via a reverse phase HPLC (Gilson) provided the title compound (17.2 mg, 30 %): MS (ES) m/z 347 (M+H)+; 1H- NMR(CDC13) δ 1.31 (d, 2H), 1.98 (m, IH), 2.28 (m, 4H), 2.39 (m, 2H), 2.67 (d, 3H), 2.79 (d, 2H), 3.66 (s, 2H), 5.82 (s, br, IH), 6.88 (s, br, IH), 7.37 (m, 10H). Example 5
Figure imgf000014_0002
3-((Endo)-8-methyl-8-aza-bicvclo[3.2.1Joct-3-yl)-2,2-diphenyl-propionic acid A solution of 2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1Joct-3-ylJ-l,l- diphenylethanol ( 100 mg, 1.56 mmol) in HCOOH (0.25 mL) was quickly added by H2SO4 (2.73 mL, 90 %) at 0°C. The reaction vial was capped immediately and stored in a refrigerator at -20°C for 7 days. The solution was poured into ice, neutralized with NH3.H2O, extracted with EtOAc and concentrated. The resultant residue was dissolved in DMSO and filtered. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (52 mg, 48 %): LCMS (ES) m/z 350 (M+H)+; Η-NMR(MeOD) δ 1.39 (d, 2H), 1.86 (m, IH), 1.97 (m, 2H), 2.30 (m, 4H), 2.69 (s, 3H), 2.84 (d, 2H), 3.69 (s, 2H), 7.28 (m, 2H), 7.36 (m, 8H). Example 6
Figure imgf000015_0001
(Endo)-3-(2-cvano-2,2-diphenyl-ethyl -8,8-dimethyl-8-azonia-bicvclor3.2.1Joctane bromide A solution of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propionitrile (310 mg, 0.938 mmol) in acetone (6.0 mL) was mixed with MeBr (4.69 mL, 2.0 M in t-BuOMe, 9.38 mmol). The resultant mixture was stirred at room temperature for 60 minutes and filtered. The solid was washed with acetone (2 x 3 mL) to afford the title compound (333 mg, 83 %): LCMS (ES) m/z 345 (M)+; 1H- NMR(MeOD) δ 1.82 (d, 2H), 2.17 (m, IH), 2.35 (m, 2H), 2.49 (m, 4H), 3.01 (d, 2H), 3.07 (s, 3H), 3.10 (s, 3H), 3.79 (s, 2H), 7.36 (m, 2H), 7.43 (m, 4H), 7.49 (m, 4H). Example 7
Figure imgf000015_0002
(Endo)-3 -(2-cyano-2 ,2-diphenyl-ethyl)- 8 , 8 -dimethyl- 8 -azonia-bicyclo [3.2.11 octane iodide A solution of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propionitrile (26.5 mg, 0.080 mmol) in CH2C12 (0.5 mL) and MeCN (0.5 mL) was mixed with Mel (0.125 mL, 2.00 mmol). The resultant mixture was stirred at room temperature for 3 hours, diluted with DMSO (0.3 mL) and concentrated. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (22.9 mg, 60 %): LCMS (ES) m/z 345 (M)+; Η-NMRfCDCl-s) δ 1.83 (d, 2H), 2.17 (m, IH), 2.35 (m, 2H), 2.49 (m, 4H), 3.01 (d, 2H), 3.07 (s, 3H), 3.10 (s, 3H), 3.79 (s, 2H), 7.36 (m, 2H), 7.43 (m, 4H), 7.49 (m, 4H).
Figure imgf000016_0001
3 -((Endo -8-methyl-8-aza-bicyclo [3.2.11 oct-3 -yl)-2,2-diphenyl-propan- 1 -ol A mixture of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propionic acid (42.5 mg, 0.122 mmol) and LiAlH, (0.488 mL, 1.0 M in THF, 0.488 mmol) was heated with a microwave reactor at 100°C for 1 hour. It was diluted with saturated Na2SO4 solution, filtered through celite and concentrated. The resultant residue was dissolved in DMSO and filtered. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (29.1 mg, 71 %): LCMS (ES) m/z 336(M+H)+; 'H-NMR^DC^) δ 1.40 (d, 2H), 1.92 (m, IH), 2.29 (m, 6H), 2.59 (m,
2H), 2.68 (d, 3H), 3.72 (s, 2H), 4.16 (s, 2H), 7.13 (m, 3H), 7.30 (m, 7H).
Example 9
Figure imgf000016_0002
N-Benzyl-3-((endo)-8-methyl-8-aza-bicvclo[3.2.1Joct-3-yl -2,2-diphenyl-propionamide A solution of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl- propionic acid (82.0 mg, 0.235 mmol) in CH2C12 (3.0 mL) was mixed with PhCH2ΝH2 (28.2 μL, 0.258 mmol), EDC (49.5 mg, 0.258 mmol), HOBt (3.2 mg, 0.024 mmol) and (CH3CH2)3N (0.232 mL, 1.65 mmol). The mixture was stirred at room temperature for 60 hours and concentrated. The resultant residue was dissolved in DMSO and filtered. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (29.8 mg, 30 %): LCMS (ES) m/z 439(M+H)+; Η-NMR(CDC13) δ 1.34 (d, 2H), 1.96 (m, IH), 2.23 (m, 2H), 2.38 (m, 4H), 2.63 (d, 3H), 2.83 (d, 2H), 3.66 (s, 2H), 4.41 (d, 2H), 6.93 (m, 2H), 7.22 (m, 3H), 7.38 (m, 10H). Example 10
Figure imgf000017_0001
(Endo -3-(2-carbamoyl-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 Joctane iodide The title compound was prepared from 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct- 3-yl)-2,2-diphenyl-propionamide by following the procedure of Example 7 (33 % yield): LCMS (ES) m/z 363 (M)+; Η-NMR(CDC13) δ 1.49 (d, 2H), 1.95 (m, IH), 2.25 (m, 2H), 2.42 (m, 4H), 2.84 (d, 2H), 3.17 (s, 3H), 3.23 (s, 3H), 3.93 (s, 2H), 5.65 (s, IH), 5.91 (s, IH), 7.39 (m, 10H). Example 11
Figure imgf000017_0002
l-Benzyl-3-[3-((endo)-8-methyl-8-aza-bicvclo[3.2.11oct-3-yl)-2,2-diphenyl-propylJ- urea
11a) 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.11oct-3-vQ-2,2-diphenyl-propylamine A solution of 3 -((endo)-8-methyl-8-aza-bicyclo [3.2.1 J oct-3 -yl)-2,2-diphenyl- propionitrile (250 mg, 0.758 mmol) in THF (2.5 mL) was mixed with BH3 (2.53 mL,
1.5 M in THF, 3.79 mmol) at 0°C. The mixture was stirred at room temperature for 20 hours and diluted with H2O (1.0 mL). The solution was then mixed with K2CO3 (0.1 g) and stirred at room temperaπire for 1 hour. Organic layers were separated and the aqueous part was extracted with EtOAc (2 x 3 mL). The organic layers were combined, dried over Na2SO4 and concentrated. Purification via a reverse phase HPLC (Gilson) afforded the titled compound (159mg, 63%): LCMS (ES) m/z 335 (M+H)+; 'H-NMR(MeOD) δ 1.35 (d, 2H), 2.01 (m, 3H), 2.34 (s, 4H), 2.55 (s, 2H), 2.68 (s, 3H), 3.73 (m, 5H), 7.26 (m, 4H), 7.33 (m, 2H), 7.43 (m, 4H). l lb) l-Benzyl-3-r3-(rendo -8-methyl-8-aza-bicvclo[3.2.noct-3-yl)-2,2-diphenyl- propyll-urea A solution of3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propylamine (50.0 mg, 0.149 mmol) in CH2C12 (2.0 mL) was mixed with PhCH2NCO (20.4 μL, 0.164 mmol) and (CH3CH2)3N (62.8 μL, 0.447 mmol). The result mixture was stirred at room temperature for 1 hours and concentrated. Purification via a reverse phase HPLC (Gilson) then afforded the titled compound (13.0mg, 19%): LCMS (ES) m/z 468 (M+H)+; Η-NMR(MeOD) δ 1.24 (d, 2H), 1.94 (m, 3H), 2.25 (m, 4H), 2.49 (d, 2H), 2.67 (s, 3H), 3.62 (s, 2H), 3.97 (s, 2H), 4.23 (s, 2H), 7.22 (m, 6H), 7.33 (m, 4H).
Figure imgf000018_0001
l-Ethyl-3-[3-((endo -8-methyl-8-aza-bicvclo[3.2.11oct-3-vπ-2,2-diphenyl-propyl1-urea The title compound was prepared from 3-((endo)-8-methyl-8-aza- bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propylamine and CH3CH2NCO by following the procedure in Example 11 (45% yield): LCMS (ES) m/z 406 (M+H)+; 1H-NMR(MeOD) δ 1.03 (t, 3H), 1.33 (d, 2H), 1.94 (m, 3H), 2.25 (m, 4H), 2.55 (d, 2H), 2.67 (s, 3H), 3.07 (q, 2H), 3.68 (s, 2H), 3.94 (s, 2H), 7.24 (m, 6H), 7.34 (m, 4H).
Figure imgf000018_0002
N-[3-((Endo)-8-methyl-8-aza-bicvclo[3.2.11oct-3-yl)-2,2-diphenyl-propyl1-acetamide A solution of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl- propylamine (33.4 mg, 0.10 mmol) in CH2C12 (0.5 mL) was mixed with Ac2O (18.9 μL, 0.20 mmol) and pyridine (16.2 μL, 0.20 mmol). The mixture was stirred at room temperature for 1 hour and concentrated. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (10.7mg, 29%): LCMS (ES) m/z 377 (M+H)+; 'H-ΝMR(MeOD) δ 1.26 (d, 2H), 1.82 (s, 3H), 1.96 (m, 3H), 2.26 (s, 4H), 2.53 (d, 2H), 2.67 (s, 3H), 3.66 (s, 2H), 4.00 (s, 2H), 7.24 (m, 6H), 7.33 (m, 4H). Example 14
Figure imgf000019_0001
N-[3-((Endo -8-methyl-8-aza-bicvclo[3.2.11oct-3-yl)-2,2-diphenyl-propyl]-benzamide The title compound was prepared from 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct- 3-yl)-2,2-diphenyl-propylamine and (PhCO)2O by following the procedure in Example 13 (8% yield): LCMS (ES) m/z 439 (M+H)+; 1H-ΝMR(MeOD) δ 1.28 (d, 2H), 2.00 (m, 3H), 2.24 (s, 4H), 2.59 (d, 2H), 2.67 (s, 3H), 3.65 (s, 2H), 4.21 (s, 2H), 7.31 (m, 6H), 7.39 (m, 6H), 7.50 (m, 3H).
Figure imgf000019_0002
3-((Endo)-8-methyl-8-aza-bicvclo[3.2.11oct-3-yl)-2.2-di-thiophen-2-yl-propionitrile The title compound was prepared from (endo)-3-iodomethyl-8-methyl-8-aza- bicyclo[3.2.1 Joctane and 2,2-di-thiophen-2-yl-acetonitrile by following the procedure in Example 2C (34 % yield): LCMS (ES) m/z 343 (M+H)+; Η-NMR(CDC13) δ 1.79 (m, 2H), 2.21 (m, 2H), 2.33 (m, 2H), 2.62 (m, 2H), 2.73 (m, 4H), 3.80 (m, 2H), 4.35 (s, 2H), 7.02 (m, 2H), 7.23 (m, 2H), 7.37 (m, 2H). Example 16
Figure imgf000020_0001
(Endo)-3-(2-cvano-2,2-di-thiophen-2-yl-ethyl)-8.8-dimethyl-8-azonia- bicyclo[3.2.noctane iodide The title compound was prepared from 3-((endo)-8-methyl-8-aza- bicyclo[3.2.1]oct-3-yl)-2,2-di-thiophen-2-yl-propionitrile by following the procedure in Example 7 (43 %): LCMS (ES) m/z 345 (M)+; Η-NMR^DC δ 1.82 (d, 2H), 2.35 (m, 2H), 2.23 (m, 3H), 2.58 (m, 4H), 2.82 (m, 2H), 3.37 (s, 6H), 4.25 (s, 2H), 7.02 (m, 2H), 7.24 (m, 2H), 7.36 (m, 2H). Example 17
Figure imgf000020_0002
N-r3-((EndoV8-methyl-8-aza-bicvclor3.2.11oct-3-yl)-2,2-diphenyl-propyll- benzenesulfonamide A solution of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propylamine (67.0 mg, 0.20 mmol) in CILCL, (2.0 mL) was mixed with PhSO2Cl (28.2 μL, 0.22 mmol) and (CHjCH^Ν (84.3 μL, 0.60 mmol). The result mixture was stirred at room temperature for 1 hours and concentrated. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (51.5mg, 54%): LCMS (ES) m/z 475 (M+H)+; 'H-NMR(MeOD) δ 1.39 (d, 2H), 2.01 (m, 3H), 2.30 (s, 4H), 2.69 (s, 5H), 3.60 (s, 2H), 3.68 (s, 2H), 7.12 (m, 4H), 7.27 (m, 6H), 7.55 (m, 2H), 7.63(m, IH), 7.78 (m, 2H). Example 18
Figure imgf000021_0001
[3-((Endo)-8-methyl-8-aza-bicvclo[3.2.1Joct-3-yl)-2,2-diphenyl-propyl]-urea To a solution of 3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propylamine (50.0 mg, 0.149 mmol) in CILC12 (4.0 mL), ClSO2NCO (31.2 μL, 0.358 mmol) was added. The mixture was stirred at room temperature for 2 days and concentrated. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (21.6mg, 38%): LCMS (ES) m/z 378 (M+H)+; 'H-NMR(MeOD) δ 1.33 (d, 2H), 2.01 (m, 3H), 2.29 (s, 4H), 2.57 (m, 2H), 2.68 (s, 3H), 3.69 (s, 2H), 4.01 (s, 2H), 7.25 (m, 6H), 7.34 (m, 4H). Example 19
Figure imgf000021_0002
N-r3-((Endo)-8-methyl-8-aza-bicyclo[3.2.11oct-3-yl -2,2-diphenyl-propyl1- methanesulfonamide The title compound was prepared from 3-((endo)-8-methyl-8-aza- bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propylamine and MeSO2Cl by following the procedure in Example 17 (28% yield): LCMS (ES) m/z 413 (M+H)+; Η-ΝMR(MeOD) δ 1.39 (d, 2H), 1.97 (m, 3H), 2.30 (s, 4H), 2.68 (s, 3H), 2.76 (s, 3H), 3.68 (s, 2H), 3.84 (s, 2H), 7.23 (s, 6H), 7.33 (s, 4H). Example 20
Figure imgf000022_0001
(Endo)-3-{2,2-diphenyl-3-[(l-phenyl-methanoyl)-aminol-propyl}-8,8-dimethyl-8- azonia-bicvclo[3.2. l}octane bromide A solution of N-[3-((endo)-8-methyl-8-aza-bicyclo[3.2. l]oct-3-yl)-2,2- diphenyl-propylj-benzamide (29 mg, 0.0683 mmol) in CFLClj (0.5 mL) and acetone (0.5 mL) was mixed with MeBr (0.342 mL, 2.0 M in t-butyl methyl ether, 0.683 mmol). The resultant mixture was stirred at room temperature for 3 hours and concentrated. Purification via a reverse phase HPLC (Gilson) then afforded the title compound (19.6 mg, 64 %): LCMS (ES) m/z 453 (M)+; 'H-ΝMR(MeOD) δ 1.20 (d, 2H), 2.32 (m, 7H), 2.65 (d, 2H), 2.98 (s, 3H), 3.02 (s, 3H), 3.60 (s, 2H), 4.22 (s, 2H), 7.30(m, 6H), 7.39(m, 6H), 7.50 (s, 3H).
BIOLOGICAL EXAMPLES
The inhibitory effects of compounds at the M3 mAChR of the present invention are determined by the following in vitro and in vivo assay:
Analysis of Inhibition of Receptor Activation by Calcium Mobilization: Stimulation of mAChRs expressed on CHO cells were analyzed by monitoring receptor-activated calcium mobilization as previously described1 . CHO cells stably expressing M3 mAChRs were plated in 96 well black wall/clear bottom plates. After 18 to 24 hours, media was aspirated and replaced with 100 μl of load media (EMEM with Earl's salts, 0.1% RIA-grade BSA (Sigma, St. Louis MO), and 4 μM Fluo-3- acetoxymethyl ester fluorescent indicator dye (Fluo-3 AM, Molecular Probes, Eugene, OR) and incubated 1 hr at 37° C. The dye-containing media was then aspirated, replaced with fresh media (without Fluo-3 AM), and cells were incubated for 10 minutes at 37° C. Cells were then washed 3 times and incubated for 10 minutes at 37° C in 100 μl of assay buffer (0.1% gelatin (Sigma), 120 mM NaCl, 4.6 mM KC1, 1 mM KH2 PO4, 25 mM NaH CO3, 1.0 mM CaCl , 1.1 mM MgCi2, 11 mM glucose, 20mM
HEPES (pH 7.4)). 50 μl of compound (lxlO"1 1 - lxlO"5 M final in the assay) was added and the plates were incubated for 10 min. at 37° C. Plates were then placed into a fluorescent light intensity plate reader (FLIPR, Molecular Probes) where the dye loaded cells were exposed to excitation light (488 nm) from a 6 watt argon laser. Cells were activated by adding 50 μl of acetylcholine (0.1-10 nM final), prepared in buffer containing 0.1 % BSA, at a rate of 50 μl/sec. Calcium mobilization, monitored as change in cytosolic calcium concentration, was measured as change in 566 nm emission intensity. The change in emission intensity is directly related to cytosolic calcium levels ' '. The emitted fluorescence from all 96 wells is measured simultaneously using a cooled CCD camera. Data points are collected every second. This data was then plotting and analyzed using GraphPad PRISM software.
Methacholine-induced bronchoconstriction
Airway responsiveness to methacholine was determined in awake, unrestrained BalbC mice (n = 6 each group). Barometric plethysmography was used to measure enhanced pause (Penh), a unitless measure that has been shown to correlate with the changes in airway resistance that occur during bronchial challenge with methacholine'2. Mice were pretreated with 50 μl of compound (0.003-10 μg/mouse) in 50 μl of vehicle (10% DMSO) intranasally, and were then placed in the plethysmography chamber. Once in the chamber, the mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes. Mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software.

Claims

What is claimed is:
1. A compound having structure I or II as indicated below except the compound of Formula (II) with R2 and R3 as 2-thiophene and R4 as -OC(O)CH3:
Figure imgf000024_0001
wherein: the H atom indicated is in the exo position;
RI" represents an anion associated with the positive charge of the N atom. RI" may be but is not limited to chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate;
R2 and R3 are independently selected from the group consisting of straight or branched chain lower alkyl groups (having preferably from 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms), heterocycloalkyl (having 5 to 6 carbon atoms) and N or O as the heteroatom, heterocycloalkyl-alkyl (having 6 to 10 carbon atoms) and N or O as the heteroatom, aryl, optionally substituted aryl, heteroaryl, and optionally substinited heteroaryl;
R4 is sleected from the group consisting of (d-C6)alkyl, (C3-C12)cycloalkyl, (C3- C7)heterocycloalkyl, (d-C6)alkyl(C3-C12)cycloalkyl, (Cι-C6)alkyl(C3-
C7)heterocycloalkyl, aryl, heteroaryl, (d-C )alkyl-aryl, (Cι-C )alkyl-heteroaryl, -OR5, -CH2OR5, -CH2OH, -CN, -CF3, -CH2O(CO)R6, -CO2R7, -CH2NH2, - CH2N(R7)SO2R5, -SO2N(R7)(R8), -CON(R7)(R8), -CH2N(R8)CO(R6), - CH2N(R8)SO2(R6), -CH2N(R8)CO2(R5), -CH2N(R8)CONH(R7); R5 is selected from the group consisting of (d-C6)alkyl, (Cι-C6)alkyl(C3- Cι2)cycloalkyl, (Cι-C6)alkyl(C3-C7)heterocycloalkyl, (Cι-C6)alkyl-aryl, (d-C6)alkyl- heteroaryl;
R6 is selected from the group consisting of (Cι-C6)alkyl, (C3-C12)cycloalkyl, (C3- C7)heterocycloalkyl, (Cι-C6)alkyl(C3-Cι2)cycloalkyl, (d-C6)alkyl(C3- C )heterocycloalkyl, aryl, heteroaryl, (Cι-C6)alkyl-aryl, (d-C )alkyl-heteroaryl;
R7 and R8 are, independently, selected from the group consisting of H, (d-C6)alkyl, (C3-Cι2)cycloalkyl, (C3-C7)heterocycloalkyl, (d-C6)alkyl(C3-Cι2)cycloalkyl, (d- C6)alkyl(C3-C7)heterocycloalkyl, (Cι-C6)alkyl-aryl, and (C1-C6)alkyl-heteroaryl.
2. A compound according to claim 1 having structure I below:
Figure imgf000025_0001
3. A compound according to claim 1 selected form the group consisting of:
(Endo)-3-(2-methoxy-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1 Joctane iodide;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl-propionitrile; (Endo)-8-methyl-3-(2,2,2-triphenyl-ethyl)-8-aza-bicyclo[3.2.1]octane;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl-propionamide;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionic acid;
(Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 Joctane iodide; (Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide;
3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propan-l-ol; N-Benzyl-3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl- propionamide;
(Endo)-3-(2-carbamoyl-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 Joctane iodide; l-Benzyl-3-[3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propylJ- urea; l-Ethyl-3-[3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea;
N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-acetamide;
N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-benzamide; 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-di-thiophen-2-yl-propionitrile;
(Endo)-3-(2-cyano-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1]octane iodide;
N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl-propylj- benzenesulfonamide; [3-((Endo)-8-methyl-8-aza-bicyclo[3.2. l]oct-3-yl)-2,2-diphenyl-propyl]-urea;
N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1 ]oct-3-yl)-2,2-diphenyl-propylj- methanesulfonamide; and
(Endo)-3-{2,2-diphenyl-3-[(l-phenyl-methanoyl)-amino]-propyl}-8,8-dimethyl-8- azonia-bicyclo[3.2.1 joctane bromide.
4. A compound according to claim 3 selected from the group consisting of:
(Endo)-3-(2-methoxy-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1 joctane iodide;
(Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 joctane iodide;
(Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 joctane bromide;
(Endo)-3-(2-carbamoyl-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1 joctane iodide; (Endo)-3-(2-cyano-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia- bicyclo[3.2.1 joctane iodide; and (Endo)-3-{2,2-diphenyl-3-[(l-phenyl-methanoyl)-amino]-propyl}-8,8-dimethyl-8- azonia-bicyclo[3.2.1 joctane bromide.
5. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
6. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.
7. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.
8. A method according to claim 7 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
9. A method according to claim 7 wherein administration is via inhalation via the mouth or nose.
10. A method according to claim 7 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
11. A method according to claim 7 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.
12. A method according to claim 11 wherein the compound has a duration of action of 24 hours or more.
13. A method according to claim 12 wherein the compound has a duration of action of 36 hours or more.
PCT/US2004/033638 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists WO2005037280A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
EA200600773A EA009899B1 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists
AP2007004239A AP2007004239A0 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists
CA2542657A CA2542657C (en) 2003-10-14 2004-10-12 Muscarinic acetylcholine receptor antagonists
DK04794886.4T DK1677795T3 (en) 2003-10-14 2004-10-12 Muscarine acetylcholine receptor antagonists
US10/575,839 US7276521B2 (en) 2003-10-14 2004-10-12 Muscarinic acetylcholine receptor antagonists
DE602004030930T DE602004030930D1 (en) 2003-10-14 2004-10-12 MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP04794886A EP1677795B1 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists
JP2006535591A JP2007508390A (en) 2003-10-14 2004-10-12 Muscarinic acetylcholine receptor antagonist
AP2006003566A AP1828A (en) 2003-10-14 2004-10-12 Muscarinic Acetycholine receptor antagonists
AP2007004238A AP2007004238A0 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists
SI200431631T SI1677795T1 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists
AU2004281724A AU2004281724B2 (en) 2003-10-14 2004-10-12 Muscarinic acetylcholine receptor antagonists
MXPA06004244A MXPA06004244A (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists.
PL04794886T PL1677795T3 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists
NZ546312A NZ546312A (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists
AT04794886T ATE494285T1 (en) 2003-10-14 2004-10-12 MUSCARINE ACETYLCHOLINE RECEPTOR ANTAGONISTS
BRPI0415361-8A BRPI0415361A (en) 2003-10-14 2004-10-12 muscarinic acetylcholine receptor antagonists
EC2006006468A ECSP066468A (en) 2003-10-14 2006-03-31 ACETILCOLINE MUSCARINIC RECEPTORS ANTAGONISTS
IL174843A IL174843A0 (en) 2003-10-14 2006-04-06 Muscarinic acetycholine receptor antagonists
IS8441A IS2918B (en) 2003-10-14 2006-05-05 Múskarínasetýlkólínviðtakamótlyf
NO20062042A NO20062042L (en) 2003-10-14 2006-05-08 Muscarinic acetylcholine receptor antagonists
US11/766,318 US7579361B2 (en) 2003-10-14 2007-06-21 Muscarinic acetylcholine receptor antagonists
US11/766,371 US7576096B2 (en) 2003-10-14 2007-06-21 Muscarinic acetylcholine receptor antagonists
IL188112A IL188112A (en) 2003-10-14 2007-12-13 8-azoniabicyclo[3,2,1]octane derivatives, pharmaceutical compositions comprising them and use thereof in the manufacture of medicamentes for the treatment of a muscarinic acetylcholine receptor mediated disease
HR20110232T HRP20110232T1 (en) 2003-10-14 2011-03-31 Muscarinic acetycholine receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51100903P 2003-10-14 2003-10-14
US60/511,009 2003-10-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/575,839 A-371-Of-International US7276521B2 (en) 2003-10-14 2004-10-12 Muscarinic acetylcholine receptor antagonists
US11/766,371 Continuation US7576096B2 (en) 2003-10-14 2007-06-21 Muscarinic acetylcholine receptor antagonists
US11/766,318 Continuation US7579361B2 (en) 2003-10-14 2007-06-21 Muscarinic acetylcholine receptor antagonists

Publications (1)

Publication Number Publication Date
WO2005037280A1 true WO2005037280A1 (en) 2005-04-28

Family

ID=34465175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033638 WO2005037280A1 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists

Country Status (34)

Country Link
US (3) US7276521B2 (en)
EP (1) EP1677795B1 (en)
JP (4) JP2007508390A (en)
KR (3) KR20060106821A (en)
CN (3) CN101230061A (en)
AP (3) AP2007004239A0 (en)
AR (1) AR046103A1 (en)
AT (1) ATE494285T1 (en)
AU (1) AU2004281724B2 (en)
BR (1) BRPI0415361A (en)
CA (1) CA2542657C (en)
CY (1) CY1111364T1 (en)
DE (1) DE602004030930D1 (en)
DK (1) DK1677795T3 (en)
EA (3) EA013435B1 (en)
EC (1) ECSP066468A (en)
ES (1) ES2358673T3 (en)
HR (1) HRP20110232T1 (en)
IL (2) IL174843A0 (en)
IS (1) IS2918B (en)
MA (1) MA28110A1 (en)
MX (1) MXPA06004244A (en)
MY (1) MY143366A (en)
NO (1) NO20062042L (en)
NZ (2) NZ556424A (en)
OA (1) OA13316A (en)
PE (1) PE20050963A1 (en)
PL (1) PL1677795T3 (en)
PT (1) PT1677795E (en)
SG (1) SG147436A1 (en)
SI (1) SI1677795T1 (en)
TW (3) TW200811172A (en)
UA (2) UA89734C2 (en)
WO (1) WO2005037280A1 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682142A2 (en) * 2003-11-04 2006-07-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007122165A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
WO2007144327A2 (en) 2006-06-12 2007-12-21 Glaxo Group Limited Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
EP1937267A2 (en) * 2005-08-02 2008-07-02 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2008070496A3 (en) * 2006-12-01 2008-09-18 Bristol Myers Squibb Co N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010097114A1 (en) * 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
JP2010539182A (en) * 2007-09-12 2010-12-16 グラクソ グループ リミテッド New combinations of therapeutic agents
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067212A1 (en) * 2009-12-01 2011-06-09 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8067408B2 (en) 2008-02-06 2011-11-29 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8071588B2 (en) 2008-02-06 2011-12-06 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8084449B2 (en) 2008-02-06 2011-12-27 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
WO2012032067A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012055846A1 (en) 2010-10-27 2012-05-03 Glaxo Group Limited Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015055690A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EP2899191A1 (en) 2009-04-30 2015-07-29 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2017137535A1 (en) 2016-02-12 2017-08-17 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as inhibitors of kinase activity
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US9795561B2 (en) 2012-12-17 2017-10-24 Glaxo Group Limited Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2018192864A1 (en) 2017-04-18 2018-10-25 Glaxosmithkline Intellectual Property Development Limited Oxepinopyrazole derivatives as inhibitors of pi3-kinase activity
WO2019020657A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Pyridine-3-sulfonamide compounds as pi3-kinase inhibitors
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (en) * 2003-07-17 2005-04-08 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
AP2007004239A0 (en) 2003-10-14 2007-12-31 Glaxo Group Ltd Muscarinic acetycholine receptor antagonists
EP1677796A4 (en) * 2003-10-17 2006-12-27 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists field of the invention
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007529513A (en) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド M3 muscarinic acetylcholine receptor antagonist
JP2007529511A (en) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド M3 muscarinic acetylcholine receptor antagonist
PE20060259A1 (en) 2004-04-27 2006-03-25 Glaxo Group Ltd QUINUCLIDINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR
JP2007537261A (en) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド Muscarinic acetylcholine receptor antagonist
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800482A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Olefinic derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (en) * 1967-06-08 1972-04-25 Siemens Ag Method for converting voltages into digital values and device for carrying out the method
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (en) 1981-07-08 1986-12-11 Draco Ab POWDER INHALATOR
FI79651C (en) 1982-10-08 1990-02-12 Glaxo Group Ltd Dosing device for medicine
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9000304D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Muscarinic receptor antagonists
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4108393A1 (en) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg NEW ESTERS BI-AND TRICYCLIC AMINO ALCOHOLS, THEIR PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
JP3294961B2 (en) * 1993-12-10 2002-06-24 杏林製薬株式会社 Novel imidazole derivative and method for producing the same
JPH08291141A (en) * 1995-04-21 1996-11-05 Kotobuki Seiyaku Kk Diphenyl acetate derivative and its production
JPH0920758A (en) * 1995-07-06 1997-01-21 Kyorin Pharmaceut Co Ltd New cyclic diamine derivative and its production
WO1998024788A1 (en) * 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NZ532283A (en) 2001-10-17 2005-06-24 Ucb S Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
DE10211700A1 (en) * 2002-03-16 2003-09-25 Boehringer Ingelheim Pharma New quaternized difurylglycolic acid azabicycloalkyl esters, useful as anticholinergic agents for treating e.g. asthma, chronic obstructive pulmonary disease, arrhythmia or menstrual disorders
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
WO2004091482A2 (en) * 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
AR048573A1 (en) * 2003-07-17 2006-05-10 Glaxo Group Ltd COMPOSITE OF 8-AZONIABICICLO [3.2.1] OCTANO REPLACED IN POSITION 3, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE THIS LAST
PE20050250A1 (en) * 2003-07-17 2005-04-08 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
UY28417A1 (en) 2003-07-17 2005-02-28 Glaxo Group Ltd ANTAGONISTS OF ACETILCOLINE MUSCARINIC RECEPTORS
AP2007004239A0 (en) * 2003-10-14 2007-12-31 Glaxo Group Ltd Muscarinic acetycholine receptor antagonists
PE20050489A1 (en) * 2003-11-04 2005-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20090258858A1 (en) 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (en) 2004-12-06 2006-10-14 Smithkline Beecham Corp COMPOUNDS OLEFINIC DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANES
PE20060826A1 (en) 2004-12-06 2006-10-08 Smithkline Beecham Corp OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
US20080275079A1 (en) 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
US20080234315A1 (en) 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439255B2 (en) * 2003-11-04 2008-10-21 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1682142A2 (en) * 2003-11-04 2006-07-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1682142A4 (en) * 2003-11-04 2009-11-25 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
EP1937267A2 (en) * 2005-08-02 2008-07-02 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007122165A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
WO2007144327A2 (en) 2006-06-12 2007-12-21 Glaxo Group Limited Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
US9102599B2 (en) 2006-12-01 2015-08-11 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008070496A3 (en) * 2006-12-01 2008-09-18 Bristol Myers Squibb Co N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
JP2010511624A (en) * 2006-12-01 2010-04-15 ブリストル−マイヤーズ スクイブ カンパニー N-((3-Benzyl) -2,2- (bis-phenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular disease
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
JP2010539182A (en) * 2007-09-12 2010-12-16 グラクソ グループ リミテッド New combinations of therapeutic agents
US8084449B2 (en) 2008-02-06 2011-12-27 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8071588B2 (en) 2008-02-06 2011-12-06 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
US8067408B2 (en) 2008-02-06 2011-11-29 Glaxo Group Limited Dual pharmacophores—PDE4-muscarinic antagonistics
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010097114A1 (en) * 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
EP3260453A1 (en) 2009-04-30 2017-12-27 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
EP2899191A1 (en) 2009-04-30 2015-07-29 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
EP3335707A1 (en) * 2009-12-01 2018-06-20 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EA023839B1 (en) * 2009-12-01 2016-07-29 Глаксо Груп Лимитед Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2011067212A1 (en) * 2009-12-01 2011-06-09 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US9750726B2 (en) 2009-12-01 2017-09-05 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP2506844B1 (en) 2009-12-01 2017-12-20 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
WO2012032067A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP3447055A1 (en) 2010-10-27 2019-02-27 Glaxo Group Limited Combinations of polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
WO2012055846A1 (en) 2010-10-27 2012-05-03 Glaxo Group Limited Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US9795561B2 (en) 2012-12-17 2017-10-24 Glaxo Group Limited Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
WO2015055690A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2017137535A1 (en) 2016-02-12 2017-08-17 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as inhibitors of kinase activity
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2018192864A1 (en) 2017-04-18 2018-10-25 Glaxosmithkline Intellectual Property Development Limited Oxepinopyrazole derivatives as inhibitors of pi3-kinase activity
WO2019020657A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Pyridine-3-sulfonamide compounds as pi3-kinase inhibitors
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Also Published As

Publication number Publication date
EA013435B1 (en) 2010-04-30
PT1677795E (en) 2011-04-01
OA13316A (en) 2007-04-13
MXPA06004244A (en) 2006-06-28
AU2004281724B2 (en) 2010-07-15
IL188112A (en) 2012-10-31
JP5450509B2 (en) 2014-03-26
AP2006003566A0 (en) 2006-04-30
EP1677795A1 (en) 2006-07-12
EA013689B1 (en) 2010-06-30
JP4796552B2 (en) 2011-10-19
IS2918B (en) 2015-01-15
IS8441A (en) 2006-05-05
US7579361B2 (en) 2009-08-25
NZ546312A (en) 2008-09-26
US7576096B2 (en) 2009-08-18
EA200600773A1 (en) 2008-04-28
EA200702619A1 (en) 2008-04-28
CN101230062A (en) 2008-07-30
IL188112A0 (en) 2008-03-20
ES2358673T3 (en) 2011-05-12
TW200522933A (en) 2005-07-16
TW200811172A (en) 2008-03-01
BRPI0415361A (en) 2006-12-12
AP2007004239A0 (en) 2007-12-31
JP2007277276A (en) 2007-10-25
NO20062042L (en) 2006-05-08
EA009899B1 (en) 2008-04-28
CA2542657C (en) 2011-03-01
CA2542657A1 (en) 2005-04-28
JP2007508390A (en) 2007-04-05
JP2011162556A (en) 2011-08-25
EP1677795B1 (en) 2011-01-05
TWI409060B (en) 2013-09-21
US7276521B2 (en) 2007-10-02
AP2007004238A0 (en) 2007-12-31
ATE494285T1 (en) 2011-01-15
NZ556424A (en) 2008-12-24
MA28110A1 (en) 2006-08-01
CN1893948A (en) 2007-01-10
UA87473C2 (en) 2009-07-27
AP1828A (en) 2008-02-13
SI1677795T1 (en) 2011-04-29
CN101230061A (en) 2008-07-30
US20070238752A1 (en) 2007-10-11
EA200702617A1 (en) 2008-04-28
PE20050963A1 (en) 2006-01-11
UA89734C2 (en) 2010-02-25
KR20060106821A (en) 2006-10-12
US20070105895A1 (en) 2007-05-10
AU2004281724A1 (en) 2005-04-28
SG147436A1 (en) 2008-11-28
AR046103A1 (en) 2005-11-23
EP1677795A4 (en) 2006-12-27
KR20080065318A (en) 2008-07-11
ECSP066468A (en) 2006-11-16
CY1111364T1 (en) 2015-08-05
KR20080067023A (en) 2008-07-17
DK1677795T3 (en) 2011-04-18
JP2007314567A (en) 2007-12-06
US20070244150A1 (en) 2007-10-18
TW200811171A (en) 2008-03-01
HRP20110232T1 (en) 2011-05-31
IL174843A0 (en) 2006-08-20
MY143366A (en) 2011-04-29
DE602004030930D1 (en) 2011-02-17
PL1677795T3 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
AU2004281724B2 (en) Muscarinic acetylcholine receptor antagonists
TW200524577A (en) Muscarinic acetylcholine receptor antagonists
US20070135478A1 (en) Muscarnic acetylchorine receptor antagonists
AU2007203078B2 (en) Muscarinic acetylcholine receptor antagonists
KR20070017965A (en) Muscarinic acetylcholine receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480037266.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 546312

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1834/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004281724

Country of ref document: AU

Ref document number: 06033251

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200602661

Country of ref document: ZA

Ref document number: 12006500705

Country of ref document: PH

Ref document number: 174843

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2542657

Country of ref document: CA

Ref document number: 2007105895

Country of ref document: US

Ref document number: 1020067007082

Country of ref document: KR

Ref document number: 10575839

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006535591

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004244

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2004281724

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004794886

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200600719

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: DZP2006000230

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200600773

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004794886

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067007082

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0415361

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10575839

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/004238

Country of ref document: AP

Ref document number: AP/P/2007/004239

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 188112

Country of ref document: IL